Lawrence Eichenfield, MD

Panelists discuss how OX40-pathway therapies may serve as first-line treatments after topicals due to their promising efficacy and safety profiles, though questions remain about optimal patient selection, long-term safety, and predictive biomarkers.

Panelists discuss how multiple OX40 pathway–targeted drugs are in development, including rocatinlimab (anti-OX40, cell depleting) and amlitelimab (anti-OX40L, nondepleting), both showing promising phase 2/3 results with potential for sustained responses.

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Panelists discuss how OX40 pathway–targeted therapies may benefit specific patient subsets with particular immunologic profiles and could potentially modify the disease course when used early, although patient selection criteria remain unclear.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines. Panelists discuss how targeting the OX40-OX40L pathway could potentially provide broader therapeutic effects across multiple T-cell subsets and offer more durable responses than current cytokine-specific or JAK inhibitor approaches.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines.

Panelists discuss how atopic dermatitis involves complex T-cell–mediated immune dysfunction beyond just Th2 pathways, with antigen-presenting cells driving naive T-cell activation and differentiation into multiple T-cell subsets that produce various inflammatory cytokines.

Panelists discuss how atopic dermatitis exhibits tremendous heterogeneity in clinical presentation, disease course, symptom variability, environmental triggers, and underlying immunologic and genetic factors that contribute to the challenge of developing one-size-fits-all treatments.

Panelists discuss how despite recent therapeutic advances in atopic dermatitis treatment, significant unmet needs remain including partial responses, lack of long-term stable control, and the need for broader patient response rates and deeper clearance levels.

Eichenfield discussed the ever-evolving armamentarium, and how to navigate changes in the field.

Eichenfield discusses safety, lab monitoring, and treatment positioning of icotrokinra in adolescents with moderate to severe plaque psoriasis.

Eichenfield discusses high skin clearance and safety in teens with psoriasis, per new ICONIC-LEAD phase 3 data.

Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.

Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.

Panelists discuss the unique challenges of managing atopic dermatitis in children compared with adults, focusing on factors such as skin barrier differences, treatment adherence, and the impact on growth and development.

Panelists discuss the mental and physical burden of atopic dermatitis on pediatric patients and their caregivers and share approaches to addressing the psychosocial impact of the condition, highlighting how these factors influence treatment selection and care strategies.

Panelists discuss how atopic dermatitis is linked to other type 2 inflammatory conditions in the pediatric population, exploring the shared immune pathways and comorbidities that connect these disorders.

Panelists discuss the pathophysiology of atopic dermatitis, highlighting the role of type 2 inflammation in driving the disease process and explaining how this inflammation contributes to the characteristic itch-scratch cycle seen in affected individuals.

Larry Eichenfield, MD, discusses how fostering transparent communication with families affected by pediatric vitiligo involves addressing their concerns, setting realistic treatment expectations, providing emotional support, and empowering parents to be advocates for their children’s physical and emotional well-being.

Larry Eichenfield, MD, discusses how pediatric vitiligo can profoundly impact a child’s mental health, self-esteem, and social relationships, requiring a comprehensive care approach that includes psychological support, family counseling, and strategies to help children navigate peer interactions and build resilience.

Larry Eichenfield, MD, discusses how vitiligo manifests uniquely in children through its earlier onset patterns, rapid progression phases, specialized diagnostic challenges for developing skin, and modified treatment approaches that must carefully balance effectiveness with safety concerns for young patients.

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.